As Trump pauses enforcement of an anti-bribery law, will pharma engage in bad behavior?

Taking stock of the drug industry, from the lab to the medicine chest

February 12, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | As Trump pauses enforcement of an anti-bribery law, will pharma engage in bad behavior? Between 2011 and 2020, 10 of the world's largest drug companies paid a combined $1.34 billion in fines for bribing foreign officials. By Ed Silverman STAT+ | Tome founders launch next venture, an RNA contract research startup The company has raised $9 million from Magnetic Ventures, Bruker Corporation, and industry veterans Hans Bishop, John Evans, and John Maraganore. By Allison DeAngelis Opinion: Gilead's short-term win threatens the future of pharmaceutical public-private partnerships This settlement could disturb the model of public-private partnership that sustains many of the United States's most important medical breakthroughs. By Christopher Morten, Ben Anderson, Charles Duan, Gregg Gonsalves, Cynthia M. Ho, Amy Kapczynski, Jordan Paradise, Reshma Ramachandran, Joseph S. Ross, Michael S. Sinha, Anthony D. So, Liza Vertinsky, and Kiran Zelbo Alex Brandon/AP Trump signs order for job cuts across federal government Elon Musk is extending his power over the federal workforce after President Trump signed an order calling for agencies to make plans to cut staff. By Associated Press

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser